https://www.selleckchem.com/pr....oducts/apr-246-prima
ICERs were most sensitive to the cost of olaparib, time horizon and discount rate for outcomes. When these parameters were varied, ICERs remained above SGD92,000 (USD69,607)/QALY.Conclusions At the current price, olaparib is not cost-effective when used with or without restriction by BRCA1/2 mutation status in Singapore, despite taking into account potential OS improvement over a long time horizon.How online social behavior covaries with real-world outcomes remains poorly understood. We examined the relationship between the f
Like
Comment
Share
